Patrick Dolezal Reiterates Buy on Surrozen, Keeps Price Target Unchanged at $44 Ahead of Key BRUNELLO Readout
I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Patrick Dolezal reiterated a Buy rating on Surrozen with an unchanged $44 price target. He anticipates favorable outcomes from Merck's upcoming BRUNELLO readout for MK-3000, viewing it as validation for Wnt agonism in ophthalmology. This supports confidence in Surrozen's SZN-8141 asset, despite potential risks being deemed unlikely.
LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on Surrozen today and set a price target of $44.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Patrick Dolezal has given his Buy rating due to a combination of factors, including the upcoming BRUNELLO readout of Merck’s MK-3000, which he sees as a key validation event for retinal Wnt agonism and, by extension, Surrozen’s ophthalmology pipeline. He views multiple potential outcome scenarios for BRUNELLO as favorable for Surrozen, particularly those that underscore the need for dual Wnt activation and VEGF inhibition, a profile embodied by Surrozen’s lead asset SZN-8141.
Dolezal considers the main downside risks—either a complete lack of efficacy or unexpected safety issues specifically tied to Wnt agonism—as relatively unlikely, given prior MK-3000 data, Merck’s visible commitment to the program, and the absence of safety-driven trial interruptions. Against this backdrop and with the BRUNELLO data expected in late Q3 or early Q4, he remains constructive on Surrozen’s shares and maintains an unchanged price target of $44, reflecting his confidence in positive read-through to the company’s Wnt-based retinal franchise.
Dolezal covers the Healthcare sector, focusing on stocks such as Neurogene, Oculis Holding, and Ibio. According to TipRanks, Dolezal has an average return of 14.6% and a 42.72% success rate on recommended stocks.